

Note: This document has been translated from the Japanese Original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese Original, the Original shall prevail.



February 25, 2026

To Whom It May Concern,

Company Name: Kubota Pharmaceutical Holdings Co., Ltd.

Title and Name of Representative: Ryo Kubota,

Representative Executive Officer,

Director, Chairman, President, and CEO

(TSE Growth: Code 4596)

Contact: Public Relations & Investor Relations, Administration Dept.

(TEL : 03-6550-8928 (main))

(Progress of Matters Previously Disclosed) Status of Discussions Toward Execution of a License Agreement with Laboratoires KÔL regarding Emixustat Hydrochloride, a Treatment Candidate for Stargardt Disease, at a Consolidated Subsidiary, Kubota Vision Inc.

Kubota Pharmaceutical Holdings Co., Ltd. (Headquarters: Minato-ku, Tokyo; the “Company”) previously announced, in its disclosure dated January 26, 2026 entitled “[Status of Discussions Toward the Execution of a License Agreement with Laboratoires KÔL Regarding Emixustat Hydrochloride, a Drug Candidate for Stargardt Disease, at a Consolidated Subsidiary.](#)” that its consolidated subsidiary, Kubota Vision Inc. (Seattle, Washington, U.S.A.; Director of the Board, Chairman, President and CEO: Ryo Kubota), had entered into a Letter of Intent (“LOI”) with Laboratoires KÔL (Clermont-Ferrand, France; Founder and CEO: Sophie Momège).

The LOI was executed to discuss and evaluate the possibility of a partnership, including a commercial collaboration, regarding emixustat hydrochloride, a drug candidate for the treatment of Stargardt disease. Based on the LOI, the parties have been engaged in discussions regarding a license agreement covering the sales rights and exclusivity of emixustat hydrochloride.

The Company has completed its review of the draft agreement and is currently conducting final confirmation of the practical details, including provisions addressing responses to unforeseen circumstances, with a view to ensuring long-term stability. Upon completion of these confirmations, the agreement is expected to be executed in the near term.

The Company will continue discussions in good faith toward the execution of the agreement and intends to promptly disclose any material developments should the agreement be finalized.

end